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Background: Accurate blood pressure monitoring is critical for the management of chronic kidney disease, but
changes in management in secondary care clinics may be based on a single blood pressure reading, with a
subsequent lack of accuracy. The aim of this study was to evaluate a fully automated sphygmomanometer for
optimising the accuracy of blood pressure measurements in the setting of secondary care renal clinics.
Methods: Patients had routine blood pressure measurements with a calibrated DINAMAP PRO400 monitor in a
clinical assessment room. Patients then underwent repeat assessment with a DINAMAP PRO400 monitor and BpTRU
device and subsequent 24 hour ambulatory blood pressure monitoring (ABPM).
Results: The BpTRU systolic (± SD) reading (117.3 ± 14.1 mmHg) was significantly lower than the routine clinic
mean systolic blood pressure (143.8 ± 15.5 mmHg; P < 0.001) and the repeat blood pressure taken with a DINAMAP
PRO400 monitor in a quiet room (129.9 ± 19.9 mmHg; P < 0.001). The routine clinic mean diastolic (82.4 ±
11.2 mmHg) was significantly higher than the BpTRU reading (78.4 ± 10.0 mmHg; P < 0.001). Clinic BpTRU
measurements were not significantly different to the daytime mean or overall mean of 24 hour ABPM.
Conclusions: In patients with CKD, routine clinic blood pressure measurements were significantly higher than
measurements using a BpTRU machine in a quiet room, but there was no significant difference in this setting
between BpTRU readings and 24 hour ABPM. Adjusting clinic protocols to utilise the most accurate blood pressure
technique available is a simple manoeuvre that could deliver major improvements in clinical practice.Background
Chronic kidney disease (CKD) affects up to 15% of the
adult population [1-4] and is associated with a high mor-
bidity and mortality. Hypertension is present in up to 90%
of people with CKD [5,6] and is the most important modi-
fiable risk factor in the clinical management of people with
CKD [7-9]. Accurate blood pressure (BP) monitoring is
therefore a critical component of the management of
people with CKD both for risk stratification and for the
appropriate use of anti-hypertensive therapy and lifestyle
modification to manage BP to recommended levels [10].
Patients at highest risk from CKD are managed in sec-
ondary care renal clinics; however, the management* Correspondence: Paul.Cockwell@uhb.nhs.uk
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reproduction in any medium, provided the orchanges that clinicians recommend in this setting are
often based on a single clinic BP reading. Use of a single
clinic measurement may over-diagnose hypertension in up
to 30% of the general population [11-13]; in many patients
identified by conventional criteria as having hypertension,
this increase in BP is confined to the clinic setting and de-
scribed as ‘white-coat hypertension’ [14,15]. If ‘white-coat
hypertension’ is not correctly identified, patients may sub-
sequently receive unnecessary antihypertensive treatment
[16]. Conversely, some patients with a normal clinic BP
reading have a high awake ambulatory BP, described as
‘masked hypertension’; the prevalence of this varies, but a
meta-analysis carried out by Bangash & Agarwal reported
a prevalence of 33% in CKD patients [17-20]; therefore
use of a single clinic BP measurement may also lead to
under-treatment in high-risk patients [13].
In addition to the shortfalls of a single BP measure-
ment, inaccuracies may be caused by operator errors;ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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appropriate cuff usage, an inadequate rest period and
overly rapid deflation rate [13,21-25]. Independently vali-
dated, fully automated sphygmomanometers may elimin-
ate many of the factors contributing to inaccurate BP
readings in clinical practice [26-28].
Ambulatory BP monitoring allows BP to be measured
over a prolonged period (normally 24 hours) and is cur-
rently considered the ‘gold standard’ for the diagnosis of
hypertension [29,30]. An additional consideration is
blunting of sleep-time decline in BP (‘non-dipping’), as
identified by ABPM; this is very common in patients with
CKD and may be an important determinant of increased
cardiovascular disease mortality [31-51]. However, there is
a significant resource implication from 24 hour ABPM, so
although it is considered cost-effective for diagnosis of
hypertension [30], it is neither cost-effective nor practical
for regular routine monitoring of BP, or for guiding
changes in antihypertensive treatment. Furthermore, pa-
tients prefer home self-measurement or clinic measure-
ment over ABPM, mainly due to the discomfort and
disturbance of life and sleep caused by the ABPM [52].
The BpTRU device is a fully automated sphygmomanom-
eter that takes six sequential BP readings at pre-set inter-
vals; it automatically discards the first reading and produces
an average BP from the last five readings. The BpTRU de-
vice has been clinically validated to British Hypertension
Society (BHS) A/A grade accuracy [26]. Studies carried out
in primary care have shown that BpTRU readings correlate
more closely with ambulatory BP readings than routine
clinic readings [29,53-55]. A single study carried out in sec-
ondary care CKD clinics showed that BpTRU readings are
lower than routine clinic BP measurements [56]. However,
the use of BpTRU monitors has not been fully evaluated
in the setting of high-risk CKD in secondary care; this is
an important shortfall in evidence, as optimisation of BP
assessment is crucial for accurate outcomes in patients
with CKD.
The aim of this study was to investigate the clinical
utility of the BpTRU device in people with CKD who are
attending secondary care clinics. To address this, we
have assessed the relationship between i) routinely taken
single BP measurements and clinic BpTRU measure-




This study was registered with the Trust Research & De-
velopment at University Hospital Birmingham as part of
a clinical service evaluation (CA2-03382-10), and fully
complies with the Declaration of Helsinki. The patients
were adults attending nephrology outpatient clinics at
the Queen Elizabeth Hospital Birmingham. Each patienthad a routine clinic BP taken by a clinic nurse in a multi-
use clinical assessment room, using a calibrated DINAMAP
PRO400 monitor (GE Healthcare, UK). The DINAMAP
PRO monitor series have been validated [57] and shown to
exceed the Association for the Advancement of Medical In-
strumentation (AAMI) standards. Subjects were seated with
their back supported, and the cuff applied to the non-
dominant arm at heart level. A single routine clinic BP
reading was taken for each individual.
After the routine clinic BP check, patients were
approached (by SB) and asked to participate in an as-
sessment of the accuracy of BP measurements. All of
the patients who were approached gave informed con-
sent; they were then allocated into one of two groups:
the first 45 consecutive patients are reported as ‘Group
A', a further 25 consecutive patients are reported as
‘Group B’. Twenty one consecutive patients attending
the outpatient department for ambulatory BP monitor-
ing and who underwent BpTRU evaluation immediately
before ambulatory BP monitoring are reported as
‘Group C’. A flow diagram summarising the BP meas-
urement schedule is shown in Figure 1.
Group A (n = 45) underwent repeat assessment with a
separate calibrated DINAMAP PRO400 monitor and then
assessment by a BpTRU device (BpTRU Medical Devices,
Coquitlam, BC, Canada) in a quiet clinic room with only
the operator present. Of this group, 24 patients had BP re-
measured with the DINAMAP PRO400 monitor. They
then had BP taken with a one-off reading with the BpTRU
monitor. This was followed by a five-minute rest period
(consistent with BHS guidelines), and then BP measure-
ment with the BpTRU device, using the full six minute
protocol. For BpTRU measurements, the patient was
seated (back supported) and the appropriate cuff size,
according to measurements on the BpTRU cuffs, was ap-
plied to the non-dominant arm (same arm as used for rou-
tine clinic BP measurement), at the level of the heart. The
BpTRU device is a fully automated sphygmomanometer,
which uses the oscillometric technique, and has been clin-
ically validated to BHS A/A accuracy [26]. It is designed to
take a series of six readings, at intervals of one minute.
The initial reading verifies that the cuff is properly posi-
tioned to obtain valid readings; this reading is then
discarded and an average of the last five readings is calcu-
lated and displayed. In this study, the interval between in-
dividual readings was set to one minute (from the start of
one reading to the start of the next), as recent studies have
shown similar readings at one or two minute intervals
[58]. The operator was present throughout all six of the
BpTRU readings; however, the patient and operator did
not interact during the BP recordings (the reason for this
was explained to the patient prior to commencing record-
ings). All six of the individual BpTRU readings, plus the
final average reading, were recorded for each patient.
Figure 1 Flow diagram showing the order of different BP measurements for Groups A, B and C.
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ment in a quiet clinic room with the BpTRU monitor,
using the full six minute protocol and with no five mi-
nute rest. Group C (n = 21) also underwent immediate
repeat assessment with the BpTRU monitor in a quiet
room (six minute protocol, no five minute rest); the pa-
tients in Group C then returned to the clinical assess-
ment room to have their ambulatory BP device (ABPM-
04 device, Meditech Ltd., Hungary) fitted. After fitting
the ABPM monitor, an initial BP reading was taken (pa-
tients sitting with their back supported and the cuff at
the level of the heart). The ABPM device was then set to
obtain automatic BP readings in accordance with pub-
lished guidelines [59]. The ABPM readings all took place
on weekdays, and patients were advised to work and be-
have as usual. Patients returned to clinic after 24 hours
and data from the ABPM was downloaded.Data analysis
Descriptive statistics were calculated for all patients in-
volved in the study (n = 91) and the three groups. Con-
tinuous variables are reported as mean ± standard
deviation throughout where normally distributed. The
analysis focused on comparisons of different BP read-
ings: i) BP measured with a DINAMAP PRO400 moni-
tor in a clinical assessment room as part of routine
clinic proceedings; ii) BP measured with DINAMAP
PRO400 monitor in a quiet clinic room; iii) BP mea-
sured with a BpTRU device in a quiet room, with orwithout a five minute rest beforehand and iv) BP mea-
sured with the ABPM device.
GraphPad Prism (Version 4, San Diego, CA, USA) was
used for all statistical analysis. Data were checked for
Gaussian distribution prior to further analysis. For data that
were normally distributed, we used analysis of variance
(ANOVA; repeated measures if paired data) to reveal sig-
nificant differences overall; Bonferroni’s multiple compari-
sons post hoc tests were then used to show specific
differences between groups. Non-Gaussian data (descriptive
statistics only) were analysed with non-parametric Kruskal-
Wallis ANOVA tests. Paired Student’s t-tests were used to
reveal significant differences between routine clinic and
BpTRU BP readings (comparing two different readings
only); noted in the relevant Figure legends. Correlation be-
tween eGFR and nocturnal ambulatory BP blunting was
assessed using Pearson’s correlation coefficient (the data
were confirmed as Gaussian prior to using this method). A
critical P value of P < 0.05 was considered significant for
the statistical tests used throughout this study. Graphically,
P < 0.05 is denoted as *, P < 0.01 as **, and P < 0.001 as ***.
Results
Ninety one patients were included in the study; 34 female
(37.4%) and 57 male (62.6%). The mean age was 49 years
(± 18.4), with a range of 16 – 83 years. There was no sig-
nificant difference in age or gender between the groups.
The overall mean estimated glomerular filtration rate
(eGFR) was 45.1 ± 24.2 (range 4 – 92) ml/ min/1.73 m2. The
overall mean albumin:creatinine ratio (ACR) was 54.6 ±
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ence in eGFR or ACR between each group (Table 1).
Measurements with BpTRU are significantly lower than
routine clinic BP measurements
The BpTRU systolic reading (122.0 ± 13.9 (96 – 150)
mmHg) was significantly lower than the routine clinic
systolic BP (149.7 ± 18.5 (117 – 209) mmHg; n = 45; P <
0.0001). The BpTRU diastolic reading (78.4 ± 10.0 (53 -
97) mmHg) was significantly lower than the routine
clinic diastolic BP (82.4 ± 11.2 (49 – 100) mmHg; n = 45;
P = 0.0033; Figure 2).
Measurements with BpTRU are significantly lower than
DINAMAP PRO400 measurements
The mean BpTRU systolic reading (117.3 ± 14.1 mmHg) was
significantly lower than both routine clinic systolic (143.8 ±
15.5 mmHg) and systolic BP taken with a DINAMAP
PRO400 monitor in a quiet room (129.9 ± 19.9 mmHg; n =
24; P < 0.001). The mean BpTRU diastolic reading (74.1 ±
9.2 mmHg) was also significantly lower than both the routine
clinic mean diastolic (78.9 ± 12.2 mmHg) and diastolic
recorded with a DINAMAP PRO400 monitor in a quiet
room (73.8 ± 10.0 mmHg; n = 24; P < 0.05; Figure 3).
The first BpTRU reading is significantly higher than the
average BpTRU reading
In our study, where the operator was present throughout
all six BpTRU readings, the mean first BpTRU measure-
ment (134 ± 23 / 81 ± 13 mmHg) was significantly higher
than the mean BpTRU average final reading (128 ± 19
80 ± 13 mmHg; n = 91; P < 0.001; Figure 4).Measurements with BpTRU do not require a five minute
rest period
Group A had a five-minute rest period between routine
clinic BP readings and BpTRU readings, whereas Group B
did not. The BpTRU systolic measurements were signifi-
cantly lower than routine clinic measurements (P < 0.001
for both Group A and Group B). However, there was no
significant difference between BpTRU systolic readings
from Group A (122.0 ± 13.9 mmHg; n = 45) and Group BTable 1 Demographic and clinical characteristics of study pop
Characteristics All patients Group A
Total number 91 45
Age (years ± SD) 49 ± 18.4 49 ± 17.6
Gender (% male) 62.6 62.2
Ethnicity (% Caucasian) 70.3 68.9
eGFR (mean ± SD) 45.1 ± 24.2 48.5 ± 25.5
ACR (mean ± SD) 54.6 ± 146.3 74.6 ± 196.(129.2 ± 16.9 mmHg; n = 25; P > 0.05; Figure 5). The five-
minute rest period did not have a significant effect on the
diastolic BP (P = 0.32).
Routine clinic BP readings are significantly higher than
ambulatory BP
In Group C patients, the routine clinic systolic reading
(159.6 ± 23.5 mmHg) was significantly higher than the
ABPM daytime mean systolic (147.5 ± 17.0 mmHg; P <
0.05) and the ABPM overall mean systolic (143.1 ±
17.5 mmHg; P < 0.001). The routine clinic diastolic read-
ing (90.5 ± 16.2 mmHg) was significantly higher than the
ABPM overall mean diastolic value (81.8 ± 15.0 mmHg;
P < 0.05; Figure 6).
BpTRU readings are not significantly different to
ambulatory BP measurements
Group C patients also had their BP measured with
BpTRU prior to 24 hour ABPM. The BpTRU mean sys-
tolic reading (140.3 ± 25.7 mmHg) was not significantly
different to either the ABPM daytime mean systolic
(147.5 ± 17.0 mmHg; P > 0.05), or the ABPM overall
mean systolic (143.1 ± 17.5 mmHg; P > 0.05). There was
no significant difference between the BpTRU diastolic
reading (89.1 ± 16.9 mmHg) and the ABPM daytime
mean (85.4 ± 15.4 mmHg; P > 0.05) or ABPM overall
mean diastolic measurements (81.8 ± 15.0 mmHg; P >
0.05; Figure 7).
Night-time ambulatory BP is significantly lower than day-
time and overall ambulatory BP, but there is a high
prevalence of nocturnal blunting
Patients in Group C (n = 21) underwent routine clinic BP
measurements, followed by BpTRU readings, prior to hav-
ing 24 hour ABPM. The night-time mean ambulatory sys-
tolic BP (135.6 ± 20.1 mmHg) was significantly lower than
both the day-time (147.5 ± 17.0 mmHg; P < 0.001) and
overall (143.1 ± 17.5 mmHg; P < 0.001) ambulatory systolic
BP readings (denoted as *** in Table 2). Similarly, the night-
time mean ambulatory diastolic BP (75.3 ± 16.2 mmHg)
was significantly lower than both the day-time (85.4 ±
15.4 mmHg; P < 0.001) and overall (81.8 ± 15.0 mmHg; P <
0.001) ambulatory diastolic BP readings (denoted as *** inulation
Group B Group C P value
25 21
60 ± 19.8 42 ± 18.4 0.54 (ns)
64 61.9 0.99 (ns)
80 61.9 0.60 (ns)
37.3 ± 22.5 47.0 ± 22.6 0.31 (ns)
7 18.6 ± 28.3 60.9 ± 87.8 0.50 (ns)
Figure 2 Comparison between routine clinic BP and BpTRU measurements. A. Bar graph showing comparison between routine clinic
systolic BP and mean systolic BP measured with BpTRU. Routine clinic systolic was significantly higher than BpTRU systolic (P < 0.0001; paired
t-test; ‘n’ in parentheses). B. Bar graph showing comparison between routine clinic diastolic BP and mean diastolic BP measured with BpTRU.
Routine clinic diastolic was significantly higher than BpTRU diastolic (P = 0.0033; paired t-test; ‘n’ in parentheses).
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nocturnal systolic BP. The mean difference between
night-time and day-time systolic BP was 6.44 ± 9.0% for
patients with an eGFR <30 ml/min/ 1.71 m2 (n = 5);
6.28 ± 2.83% for patients with an eGFR from 30-59 ml/
min/ 1.73 m2 (n = 10) and 12.80 ± 8.12% for patients
with an eGFR ≥60 ml/min/ 1.73 m2 (n = 6). There was
a positive correlation (non-significant) between eGFR
and difference between day-time and night-time systolic
BP (Pearson’s correlation coefficient = 0.31; P = 0.17); theFigure 3 Comparison between DINAMAP PRO400 and BpTRU measur
systolic BP, systolic BP measured with the DINAMAP PRO400 monitor in a q
measures) showed a significant overall difference (P < 0.0001); Bonferroni’s
reading was significantly higher than both the reading with the DINAMAP
(P < 0.001). The BpTRU reading was also significantly lower than the readin
Bar graph showing comparison between mean diastolic BP values, measur
overall difference (P = 0.0073); Bonferroni’s multiple comparison post hoc te
both the reading taken with the DINAMAP PRO400 monitor in a quiet roomlack of statistical significance may reflect the relatively
small numbers who underwent ABPM in the study.
Discussion
This study showed that the use of BpTRU in an out-
patient CKD clinic leads to significantly more accurate
BP measurement (using 24 hour ABPM as a gold stand-
ard) than BP obtained with a conventional BP monitor
(DINAMAP PRO400); in this study, there was no signifi-
cant statistical difference between BP readings takenements. A. Bar graph showing comparison between routine clinic
uiet room, and systolic BP recorded with BpTRU. ANOVA (repeated
multiple comparison post hoc test showed that the routine clinic
PRO400 monitor in the quiet room (P < 0.001) and the BpTRU reading
g with a DINAMAP PRO400 monitor in the quiet room (P < 0.001). B.
ed as described in A. ANOVA (repeated measures) showed a significant
st showed that the routine clinic reading was significantly higher than
(P < 0.05) and the reading taken with BpTRU (P < 0.05).
Figure 4 Comparison between first BpTRU reading and average BpTRU reading. A. Combined data for all patients, showing mean
individual and average BpTRU systolic readings. ANOVA (repeated measures) showed a significant difference (P < 0.0001). Bonferroni’s multiple
comparison post hoc test showed that the mean first BpTRU systolic measurement (± SD) (133.8 ± 22.5 mmHg) was significantly higher than the
final average BpTRU systolic measurement (127.9 ± 19.0 mmHg; n = 91; P < 0.001). B. Combined data showing mean individual and average
BpTRU diastolic readings. ANOVA (repeated measures) showed a significant difference (P < 0.0001); the subsequent Bonferroni’s post hoc test
showed that the mean first BpTRU diastolic reading (81.2 ± 13.3 mmHg) was significantly higher than the final average BpTRU diastolic reading
(80.2 ± 13.0 mmHg; n = 91; P < 0.001).
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The results show a hierarchy of increasing accuracy
from single clinic BP measurements to BpTRU on full
protocol; these differences in BP, when measured under
different conditions, have important clinical implications
and may lead to inaccurate BP management.
In addition, we have shown that BpTRU measurements
taken in a quiet clinic room are significantly lower than
the readings obtained with a DINAMAP PRO400 device
in the same setting. We have also demonstrated that, in
the presence of an operator, the first BpTRU reading is
still significantly higher than the average BpTRU reading.
A number of primary care studies have investigated the
difference between routine office BP measurements andFigure 5 Effect of five minute rest period on systolic BP. Bar
graph showing the difference between routine clinic systolic and
BpTRU systolic, with or without a 5 minute rest period prior to
BpTRU measurements. ANOVA showed a significant overall
difference (P < 0.0001); Bonferroni’s multiple comparison post hoc
test showed significant differences between routine clinic systolic
and BpTRU average systolic for both Group A (P < 0.001) and Group
B (P < 0.001). The mean systolic BpTRU readings were not
significantly different between Group A and Group B (P > 0.05).average BpTRU readings. Three studies restricted their
subjects to patients with an existing diagnosis of hyperten-
sion [29,33,34]; one study included both hypertensive and
normotensive patients [39]. Beckett & Godwin showed that
average BpTRU readings were significantly lower than the
average of the routine office BP measurements taken at the
last three clinic visits [29]. Myers et al. (2011) compared
BpTRU readings with the most recent manual routine of-
fice BP. Their study also showed that average BpTRU read-
ings were significantly lower than the routine office BP
readings [34]. Myers et al. (2008) compared BpTRU read-
ings with mean office manual BP readings taken on the
same day. For the office readings in their study, four con-
secutive readings were taken at one minute intervals; the
first reading was then discarded and the mean of the last
three readings was recorded. Their results showed that the
average BpTRU reading was significantly lower than the
mean office BP [39]. Another study, also restricted to
hypertensive patients, compared average BpTRU readings
with the mean of three BP measurements auscultated sim-
ultaneously by a Hypertension Nurse Specialist using an
aneroid sphygmomanometer (linked to the same cuff using
‘Y’ tubing). This study found that, although there was 92%
agreement between BpTRU readings and those measured
by the Hypertension Nurse Specialist, there was still a sig-
nificant difference in the readings [25]. The results that we
present from this current study are therefore consistent
with these previously published studies.
However, there are several differences between this
study and previous studies carried out in primary care.
Firstly, our measurements were taken in a secondary care
outpatient clinic. Secondly, patients in this study were at-
tending for routine appointments, rather than to partici-
pate in the study. Thirdly, all the patients had CKD;
accurate BP assessment and management is particularly
important in this patient group, as people with CKD are at
very high risk of cardiovascular disease and hypertension
is the major treatable risk factor for this complication.
Figure 6 Comparison between routine clinic readings and ambulatory BP. A. Bar graph comparing routine clinic systolic BP with the
daytime and overall mean systolic readings obtained through ABPM. ANOVA (repeated measures) showed a significant overall difference (P <
0.0001). Bonferroni’s multiple comparisons post hoc tests showed that the routine clinic systolic reading was significantly higher than the ABPM
daytime (P < 0.05) and ABPM overall (P < 0.001) systolic readings. B. Bar graph comparing routine clinic diastolic BP with the daytime and overall
mean diastolic readings obtained through ABPM. ANOVA (repeated measures) showed a significant overall difference (P < 0.0001). Bonferroni’s
multiple comparisons post hoc tests showed that the routine clinic diastolic reading was significantly higher than ABPM overall diastolic
reading (P < 0.05).
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ies have been taken with manual sphygmomanometers;
this study compared average BpTRU readings to BP mea-
surements taken with a DINAMAP PRO400 device, an
automated sphygmomanometer which, like the BpTRU
device, also uses the oscillometric technique.
A recent study compared BpTRU readings with routine
clinic BP measurements in secondary care clinics [35]. The
patients involved in the study had existing diagnoses of
CKD and hypertension, and were attending for routine
clinic appointments. Patients had their BP recorded with a
BpTRU device (no five minute rest) prior to having their
routine clinic BP measured with an automated monitor.
The study showed that routine clinic BP readings were sig-
nificantly higher than BpTRU readings, which is consistent
with the results of our study and previously published workFigure 7 Comparison between BpTRU measurements and ambulatory
and overall mean systolic readings obtained through ABPM. ANOVA (repeated
readings and either the daytime mean or overall mean ABPM readings (P > 0.
and overall mean diastolic readings obtained through ABPM. ANOVA (repeatefrom primary care. However, there are differences between
this study and our current work. Firstly, our study does not
limit the patient population to those with existing hyper-
tension. Secondly, in our study, an observer was present
throughout the recordings; this is more practical for rou-
tine use in the busy outpatient setting. Finally, our work
further investigates the potential use of BpTRU in second-
ary care clinics by comparing BpTRU readings to ABPM
(gold standard) measurements collected on the same day.
Several previous studies showing a significant differ-
ence between BpTRU and routine clinic measurements
have included a five-minute rest prior to carrying out
measurements with BpTRU, as per the BHS guidelines
[25,29,54,60]. However, recent studies have shown that,
in the absence of the five-minute rest, the significant dif-
ference between average BpTRU readings and routineBP. A. Bar graph comparing systolic BpTRU readings with the daytime
measures) showed no significant differences between the BpTRU
05). B. Bar graph comparing diastolic BpTRU readings with the daytime
d measures) showed no significant differences (P > 0.05).
Table 2 Comparison between ambulatory BP readings
Systolic Diastolic
ABPM day-time 147.5 ± 17.0 85.4 ± 15.4
ABPM night-time 135.6 ± 20.1*** 75.3 ± 16.2***
ABPM overall 143.1 ± 17.5 81.8 ± 15.0
% difference between night and day BP 8.2 ± 6.7%
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in the setting in which this current study was carried out,
average BpTRU readings are significantly lower than rou-
tine clinic readings in the presence or absence of the five-
minute rest period, confirming that the five minute rest
period is not essential with BpTRU. Furthermore, there
was no significant difference detected between average
BpTRU readings obtained without a five minute rest
period, and the daytime mean or overall mean of 24 hour
ABPM demonstrating the accuracy of the BpTRU readings
without the five minute rest.
The first BpTRU reading was significantly higher than
the average BpTRU reading. This is in agreement with
results reported by previous studies [29,55,61]. In these
studies, however, the operator was present for the first
BpTRU reading, but then left the patient alone from the
second reading onwards. One study reported that the
initial reading with BpTRU (observer present) was not
significantly different to the manual office reading (ob-
server also present), but that the average BpTRU reading
(observer absent) was significantly lower than both of
these [61]. This difference between the first and average
BpTRU readings has therefore been attributed to the
white coat effect, with the conclusion that it is the act of
the observer leaving the patient, which results in the
subsequently lower BP readings. Indeed, Myers et al.
(2011) commented “the simple presence of an observer
seems to increase BP, as marked decreases in automated
office BP are evident within two minutes of the observer
leaving the room” [55]. A separate study included mean
BP measurements taken with a home automated sphyg-
momanometer, self-activated (five times, at one minute
intervals) by patients sitting alone in a quiet room. They
found that, in hypertensive patients, the mean of these
self-measured BP readings was significantly higher than
both BpTRU readings and awake ABPM readings [53],
suggesting that the differences between BpTRU and
other methods of BP measurement are not only down to
the fact that the BpTRU device enables the observer to
be absent during the BP recordings. In our study, the
operator was present throughout all six of the BpTRU
readings, although there was no interaction between the
operator and patient during the readings. In the busy
outpatient setting, it is not possible to have separate
rooms for each patient having their BP measured. Our
results confirm that, even in the presence of an operator,the average BpTRU reading is still significantly lower
than the first BpTRU reading, and there is still a marked
decrease in BP within the first three BpTRU readings.
Night-time ambulatory BP readings were significantly
lower than the daytime and overall ambulatory BP read-
ings. However, a blunted sleep-time decline (“non-dip-
ping”; <10% difference between day-time and night-time
systolic BP) in BP was common; a finding consistent with
other studies that have assessed people with CKD [31-35].
Blunted sleep-time decline has been associated with an in-
creased incidence of cardiovascular disease in CKD and
other settings [35-51]; this has important implications
for the management of BP in people with CKD
[35,36,40,45,46,62-76]. The current study was cross-
sectional and not powered to assess the relationship be-
tween blunting and clinical outcomes or the impact of
optimisation of BP management on nocturnal blunting.
In this study, there was no detectable difference between
average BpTRU readings obtained in outpatient clinics
and the daytime mean or overall mean readings from
24 hour ABPM; again, this is consistent with other pub-
lished studies [29,53-55]. Beckett & Godwin found that
there was no significant difference between average
BpTRU readings and the daytime mean of ABPM carried
out on the same day [29]. A second study showed that
average BpTRU readings correlate better with awake am-
bulatory readings than mean routine office BP measure-
ments [54]. A third study also found that the correlation
between BpTRU readings and awake ambulatory BP was
stronger than that between routine office BP readings and
awake ambulatory BP, although there was still a significant
difference between BpTRU and ABPM readings [55].
However, the ABPM readings in this study were obtained
at an unspecified length of time prior to patients having
their BpTRU readings taken [55]. The data that we report
in this paper provide the first evidence that, in a true clin-
ical setting involving patients with CKD attending out-
patient clinics, there is no discernible difference between
average BpTRU readings and the daytime mean of 24 hour
ambulatory BP monitoring carried out on the same day.
Regular, accurate BP assessment and management is par-
ticularly important in these patients, as hypertension is a
major treatable risk factor for cardiovascular disease.
One shortfall of the study is the absence of 48-hour
ABPM data. A recent consensus recommendation con-
cluded that 48-hour ABPM should be utilised for assess-
ment of hypertension, including patients with CKD [76].
The data presented in this study predate that recommenda-
tion; the recently updated European Hypertension guidelines
only refer to 24-hr ABPM [77], as does the UK NICE Hyper-
tension guideline [78]. Therefore, for most clinicians, 24-hr
ABPM remains the clinical standard of care for ambulatory
BP assessment and the data shown in this paper should be
of practical value. However, clinicians should be aware that
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an important option for investigation.
Other limitations to this study include: i) this study was
performed in a clinical setting, rather than a research set-
ting, unlike the majority of previously published work in
this area. Therefore, BpTRU readings were always carried
out following the routine clinic BP measurements; ii) pre-
vious studies have taken routine clinic BP measurements
and BpTRU measurements in random order; this is clearly
a more accurate way to compare the two techniques, and
iii) routine clinic BP measurements were not consistently
carried out following a five-minute rest period, unlike
those reported in the literature. In a busy outpatient set-
ting, some patients had their routine clinic BP measured
as soon as they arrived at clinic; others had their routine
clinic BP measured after sitting in the waiting room for a
variable amount of time. This lack of control over the tech-
nique used for the routine clinic BP measurements may be
responsible for some of the difference observed between
these readings and the subsequent BpTRU readings. It is
also important to emphasise that data from a single study
carried out in one setting may not be applicable to other
settings. However, in previous studies, where routine clinic
BP measurements were carried out in a more controlled
manner, average BpTRU readings were also significantly
lower than routine clinic readings, suggesting that the data
we present are broadly consistent with previous findings
and also confirming that previous work carried out in a re-
search setting may be applicable to routine clinical practice.
Conclusions
In conclusion, our study demonstrates that routine
clinic BP measurements are significantly higher than
measurements using a BpTRU machine in a quiet room,
and there is no significant detectable difference between
BpTRU readings and the day-time mean of 24 hour
ABPM in patients with CKD. Adjusting clinic protocols
to utilise the most accurate BP device available is a sim-
ple manoeuvre that could deliver major improvements
in clinical practice.
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